---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-009118"
form_type: "8-K"
ticker: null
cik: "0001629205"
company_name: "Innovation1 Biotech Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:30:08.681653+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Innovation1 Biotech raises $150k via secured convertible notes and warrants

## Summary
- Gross proceeds of $150,000 from $176,472 principal notes at 8% interest, mature Jan 6, 2025.
- 2,205,882 common stock purchase warrants issued at exercise price of $0.08 per share.
- Notes convertible into common stock at $0.08 per share, with 4.99% beneficial ownership limit.
- Transaction exempt from registration under Rule 506(b) of Securities Act.

## SEC filing metadata
- accession: 0001477932-23-009118
- form_type: 8-K
- cik: 0001629205
- company_name: Innovation1 Biotech Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/ivbt_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-009118
- JSON: https://secwatch.observer/filing/0001477932-23-009118.json
- Plain text: https://secwatch.observer/filing/0001477932-23-009118.txt

## Key facts
- Debt Financings
  Innovation1 Biotech Inc. incurred convertible notes of $176,472 with three lenders (the “Purchasers”) at 8% per annum maturing January 6, 2025.
  - Instrument: convertible notes
  - Principal: $176,472
  - Counterparty: three lenders (the “Purchasers”)
  - Rate: 8% per annum
  - Maturity: January 6, 2025
  - Event: incurrence
  source text: On December 7, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with three lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $176,472 (collectively, the “Notes”) for gross proceeds of $150,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm
- Material Agreements
  Innovation1 Biotech Inc. entered into Securities Purchase Agreement with three lenders (the "Purchasers") valued at $176,472 (effective 2023-12-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: three lenders (the "Purchasers")
  - Value: $176,472
  - Effective: 2023-12-07
  source text: On December 7, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with three lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $176,472
  evidence_url: https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.